Cell Source is an immunotherapy and regenerative medicine company whose primary breakthrough is the regulation of immune tolerance. In preclinical studies, Cell Source’s therapies have demonstrated the ability to directly address a number of severe medical conditions, including blood cancers such as non-Hodgkins lymphoma, multiple myeloma and chronic lymphocytic leukemia. The company’s organ regeneration platform holds the potential to repair organs and to grow entire organs inside the patient’s body. For more information, visit the company’s website at www.cell-source.com